Chronic hepatitis C in Russia: current challenges and prospects

Chulanov, Vladimir; Pimenov, Nikolay; Мамонова, Н. А.; Sagalova, Olga; Shestakova, I.; Pokrovsky, V I

doi:10.17116/terarkh201587115-10

Cited by 21 publications

(3 citation statements)

References 14 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Modelling studies at the national and sub-national/regional levels in Russia show that HCV prevalence is expected to rise by 2030, 39 , 40 emphasizing the importance of accelerating access to safe and effective treatments. The scale-up of testing and treatment with the new drugs is a key strategic intervention set by WHO to achieve the treatment coverage targets for elimination of viral hepatitis as a public health threat by 2030.…”

Section: Discussionmentioning

confidence: 99%

Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice

Malik

Chulanov

Pimenov

et al. 2022

Journal of Virus Eradication

View full text Add to dashboard Cite

Section: Discussionmentioning

confidence: 99%

Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice

Malik

Chulanov

Pimenov

et al. 2022

Journal of Virus Eradication

View full text Add to dashboard Cite

“…Истинная распространенность ХГС остается неизвестной из-за несовершенства форм государственной статистической отчетности, однако, по экспертным оценкам, в РФ ХГС встречается у 2-5 млн человек, большая часть ко торых -молодые люди в возрасте от 20 до 40 лет. [1,4]. При этом, по данным анализа регистра больных ХВГ, лечение получают только 2,4% пациентов с ХГС [5].…”

Section: Introductionunclassified

Cost-effectiveness Analysis of Elbasvir and Grazoprevir for Treatment of Adult Patients with Chronic Hepatitis C (genotype 1b) from Russian Healthcare System Perspective

Pyadushkina

Boyarskaya

Derkach

et al. 2018

Medical Technologies. Assessment and Choice (Медицинские Технологии. Оценка И Выбор)

View full text Add to dashboard Cite

Objective. Cost-effectiveness analysis (CEA) of elbasvir in combination with grazoprevir (EBR/GZR) for the treatment of patients with chronic hepatitis C (CHC), infected with genotype 1 subtype b, who previously did not receive antiviral therapy (AVT), without cirrhosis or with compensated cirrhosis, from a Russian healthcare system perspective. Methods. In a model, developed in MS Office (Microsoft Excel® package), the differences in direct medical costs were determined (using cost minimization analysis) by comparing EBR/GZR and 3D (the combination of ombitasvir, paritaprevir, ritonavir, and dasabuvir), which have comparable effectiveness in patients with chronic hepatitis C (genotype 1b). Besides, changes in costs for the treatment of patients with CHC (genotype 1b), if EBR/GZR are reimbursed, are analysed under the State-guaranteed benefit package (SGBP) for free medical care for the citizens of the Russian Federation (budget impact analysis). Frequencies of long-term consequences of CHC (number of cases of decompensated cirrhosis and hepatocellular carcinoma) were projected in the long run depending on whether AVT is administered or not, for 20 years or lifetime time horizon. For calculations, data from literature and standard financial expenditures in Russian healthcare system in 2018 were used. Univariate (one-way) sensitivity analysis was conducted to assess the impact in the price change of EBR/GZR package on the results of the analysis. Results. Average cost per patient for therapy with EBR/GZR was 510 142 rubles, or 21% less than for therapy with 3D that was 645 614 rubles. If EBR/GZR are included in Vital and Essential Drugs List (VED), expenditures under SGBP for treatment of CHC (genotype 1b) are expected to decrease by 16,1% in three years: by 9,4% in the first year, 15,7% in the second year and by 21% in the third year. Conclusions: Using EBR/GZR in clinical practice is efficient and leads to an improvement in the competitiveness in the field. It also allows reducing the additional healthcare system expenditures on direct-acting antiviral agents (DAAA) in AVT of CHC, and provides highly-effective therapeutic regimes under SGBP for patients without increasing the budget. Greater accessibility of DAAA (EBR/GZR and 3D) within the Russian healthcare system and increased availability of these drugs for the patients will lead to a significant decrease in incidence of such severe and costly consequences of hepatitis as decompensated cirrhosis and hepatocellular carcinoma in comparison with no treatment in the long run.

show abstract

“…В настоящее время сохраняется высокая медико-социальная значимость НСV-инфекции. Это обусловлено широтой ее распространения, отсутствием специфической профилактики, высоким уровнем инфицированности населения и тяжестью неблагоприятных исходов (цирроз печени и гепатоцеллюлярная карцинома) [1,2]. Эрадикационная терапия препаратами прямого противовирусного действия (ПППД) позволяет практически каждому пациенту иметь шанс излечения.…”

Section: Introductionunclassified

Clinico-laboratory and immunological characteristics of patients with compensated cirrhosis of the liver in the outcome of chronic hepatitis C on the background of treatment with a direct antiviral drug paritrapeprir/ritonavir/ombitasvir/ dasabuvir

Popova

Konstantinov

Strebkova

et al. 2018

test

View full text Add to dashboard Cite

Goal. Paritrapeprir / ritonavir / ombitasvir / dasabuvir on the clinical and laboratory parameters, including thesubpopulation composition of lymphocytes, in patients with compensated cirrhosis in the outcome of chronic hepatitis C. Materials and methods. The study included patients with compensated liver cirrhosis class A (no more than 6 on the Child – Turcotte – Pugh scale), in the outcome of chronic hepatitis C, genotype 1b (group 1, n = 28). The comparison group (group 2, n = 25) consisted of patients comparable in terms of gender and main study parameters, not receiving antiviral therapy. Results. A stable virologic response was 96,8%. There were no serious adverse events requiring treatment reversal. As a result of treatment, there was a disappearance or a significant decrease in the severity of asthenovegetative and dyspeptic syndromes, a reduction in liver size, an improvement in liver functional parameters (biochemical response), and normalization of the balance of the cellular immunity by increasing CD3 +, CD4 +, CD8 + – CD16 + lymphocyte counts. The conclusion. Etiotropic therapy with paritrapeprir /ritonavir / ombitasvir / dasabuvir is well tolerated by patients with compensated cirrhosis in the outcome of chronic hepatitis C, has high efficacy, positively influences the dynamics of clinical manifestations, and also helps reduce the imbalance of the cellular immunity.

show abstract

Chronic hepatitis C in Russia: current challenges and prospects

Abstract: This paper evaluates the impact of different medical care strategies for chronic hepatitis C patients in relation to its prevalence, frequency of adverse outcomes and mortality rate.

Cited by 21 publications

References 14 publications

Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice

Treatment and monitoring of children and adolescents with hepatitis C in Russia: Results from a multi-centre survey on policy and practice

Cost-effectiveness Analysis of Elbasvir and Grazoprevir for Treatment of Adult Patients with Chronic Hepatitis C (genotype 1b) from Russian Healthcare System Perspective

Clinico-laboratory and immunological characteristics of patients with compensated cirrhosis of the liver in the outcome of chronic hepatitis C on the background of treatment with a direct antiviral drug paritrapeprir/ritonavir/ombitasvir/ dasabuvir

Contact Info

Product

Resources

About